TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Modalis Therapeutics Corporation ( (JP:4883) ) has issued an update.
Modalis Therapeutics Corporation has announced the issuance of 700 new shares as part of a restricted-stock-based remuneration plan for an employee of its subsidiaries. This initiative aims to enhance the company’s long-term corporate value and align the interests of its employees with those of its shareholders. The issuance is part of a broader compensation strategy approved in 2021, designed to reward contributions to the company while maintaining a minimal impact on share dilution.
More about Modalis Therapeutics Corporation
Modalis Therapeutics Corporation is a company listed on the Tokyo Stock Exchange, operating within the biotechnology industry. The company focuses on developing innovative therapeutics, particularly in the realm of genetic medicine, to address unmet medical needs.
Average Trading Volume: 4,181,503
Technical Sentiment Signal: Sell
Current Market Cap: Yen7.15B
See more data about 4883 stock on TipRanks’ Stock Analysis page.